

## Special Issue

# Recent Research on Adenovirus-Vectored Vaccines

### Message from the Guest Editors

As we move forward from the COVID-19 pandemic and focus on both emerging and previously recognized pathogens, we invite you to contribute to a Special Issue on 'Recent Research on Adenovirus-vectored Vaccines'. The pandemic has provided valuable insights into the development of vaccines against coronaviruses and other viruses. Replication-deficient viral vaccines have been shown to effectively induce neutralizing antibodies and cellular immune responses, thereby providing adequate immune protection.

This Special Issue is an opportunity to address these experiences. **We are interested in studies that examine the persistence of immune responses after vaccination against SARS-CoV-2, other pathogens, or cancers, especially in comparison to other vaccine platforms. We also welcome comparisons among different types of adenovirus vaccines, including replicating, single-cycle, replication-defective, and helper-dependent variants and different serotypes.**

---

### Guest Editors

Dr. Michael A. Barry

Departments of Medicine, Immunology, and Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA

Dr. Vijay S. Reddy

The Hormel Institute, University of Minnesota, Austin, MN 55912, USA

---

### Deadline for manuscript submissions

31 May 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/242722](https://mdpi.com/si/242722)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).